Changeflow GovPing Pharma & Drug Safety HTO Nevada Inc. Recalls Lidocaine Cream Due to ...
Urgent Enforcement Removed Final

HTO Nevada Inc. Recalls Lidocaine Cream Due to Stability Data

Favicon for changeflow.com FDA: Drug Recalls Class II
Filed
Detected
Email

Summary

HTO Nevada Inc. is recalling its MAXIMUM, ZONE 1, 4% Lidocaine Cream (NDC 80069-014) nationwide due to stability data not supporting the expiry date. This is a Class II recall, indicating that use of or exposure to the product may cause temporary or medically reversible adverse health consequences.

What changed

HTO Nevada Inc., doing business as Kirkman, is initiating a Class II recall for its MAXIMUM, ZONE 1, 4% Lidocaine Cream (NDC 80069-014) distributed nationwide. The reason for the recall is that the stability data does not support the product's stated expiry date, raising concerns about product efficacy and safety over time.

This recall requires immediate action from distributors and potentially consumers who may possess the affected product. While classified as Class II, which suggests less severe health risks than Class I recalls, the product's integrity is compromised. Companies involved in the distribution chain must ensure the product is removed from inventory and accounted for according to recall procedures. The FDA will monitor the effectiveness of this recall to ensure the product is no longer available to consumers.

What to do next

  1. Remove affected Lidocaine Cream from inventory
  2. Comply with FDA recall procedures for Class II recalls

Archived snapshot

Mar 28, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

HTO Nevada Inc. dba Kirkman

Drug Recalls (Class II)

← All Drug Recalls (Class II) Class II D-0386-2026 · 20260311 · Ongoing

Product

MAXIMUM, ZONE 1, 4% Lidocaine Cream, 1/2 oz bottles, Distributed By: Dermal Source, Portland, OR 97232, NDC 80069-014.

Reason for Recall

Stability Data Does Not Support Expiry Date.

Distribution

Nationwide within the U.S

Source: openFDA Enforcement API

Get daily alerts for FDA: Drug Recalls Class II

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
FDA
Filed
March 11th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
D-0386-2026

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Recalls Product Labeling
Threshold
Class II recall
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11
Topics
Product Safety Drug Recalls

Get alerts for this source

We'll email you when FDA: Drug Recalls Class II publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!